1.An excerpt of ESMO clinical practice guideline interim update on the management of biliary tract cancer in 2025
Delong QIN ; Yue TANG ; Zonglong LI ; Jialu CHEN ; Zhaohui TANG ; Zhiwei QUAN
Journal of Clinical Hepatology 2025;41(4):625-627
In January 2025, the European Society for Medical Oncology (ESMO) released the ESMO clinical practice guideline interim update on the management of biliary tract cancer as a supplementary update to Biliary tract cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up published in November 2022. This interim update mainly revises the latest evidence-based medical recommendations in the key fields of molecular diagnostics and clinical management since the release of the original guidelines, and it is not a comprehensive update of the entire document. This article summarizes and makes an excerpt of the new recommendations from this interim update.
2.Clinical and pathological features and prognostic analysis of early-onset intrahepatic cholangiocarcinoma
Delong QIN ; Yue TANG ; Zonglong LI ; Jialu CHEN ; Zhimin GENG ; Chuandong SUN ; Hong WU ; Yinghe QIU ; Tianqiang SONG ; Xianhai MAO ; Yu HE ; Zhangjun CHENG ; Wenlong ZHAI ; Jingdong LI ; Xiao LIANG ; Ruixin LIN ; Di TANG ; Zhaohui TANG ; Zhiwei QUAN
Chinese Journal of Surgery 2025;63(6):500-507
Objective:To explore the clinical and pathological features and survival outcomes of patients with early-onset intrahepatic cholangiocarcinoma (EOICC).Methods:This is a multicenter, retrospective cohort study. Data of 1 160 intrahepatic cholangiocarcinoma patients undergoing radical resection in 14 tertiary Grade A hospitals in China from January 2010 to November 2021 were retrospectively collected. The cohort included 632 males and 528 females, aged( M (IQR)) 61 (14) years (range: 22 to 93 years). ICC aged ≤50 years at the time of diagnosis was defined as EOICC and >50 years as late-onset intrahepatic cholangiocarcinoma (LOICC). Of these, there were 247 cases in the EOICC group and 913 cases in the LOICC. The clinical and pathological characteristics of both groups were analyzed and compared using the independent sample t-test, Mann-Whitney U test or Kaplan-Meier method. Univariate and multivariate Cox regression models for patient outcomes were constructed and forest graphed. Results:Compared with the patients in the LOICC group, patients in the EOICC group had lower carcinoembryonic antigen levels (2.5(4.0) μg/L vs. 3.1(5.2)μg/L, U=124 899, P=0.009) and CA19-9 level (63.4(524.7)U/ml vs. 77.9(611.3)U/ml, U=120 320, P=0.013), higher levels of ALT (29(35)U/L vs. 24(26)U/L, U=101 214, P=0.013), a lower score of the Eastern US Cooperative Oncology Group (0 score patients: 54.7% vs. 44.1%, χ2=12.472, P=0.014), higher TNM stage ( χ2=11.807, P=0.038), and proportion of lymph node dissection (62.3% vs. 54.1%, χ2=5.355, P=0.021). Patients in the two groups in sex, first diagnosis symptoms, intrahepatic bile duct stone history, nail protein, albumin, total bilirubin, transaminase, liver function Child-Pugh grade, T stage, stage, N stage, preoperative laparoscopic exploration proportion, tumor diameter, vascular invasion proportion, differentiation, margin, intraoperative bleeding, postoperative complications, postoperative hospital days were no statistical significance (all P>0.05). Patients in the EOICC group had better outcomes than the LOICC group (median survival time: 29.7 months vs. 25.0 months, 3-year overall survival: 45.1% vs. 37.8%, P=0.027). Conclusion:EOICC patients are better than LOICC patients in carcinoembryonic antigen, CA19-9, ALT, physical strength status and TNM stage, and the long-term prognosis is also better than LOICC patients.
3.Identification and management strategies for postoperative recurrence of intrahepatic cholangiocarcinoma
Delong QIN ; Yue TANG ; Zonglong LI ; Jialu CHEN ; Zhaohui TANG ; Zhiwei QUAN
Chinese Journal of Surgery 2025;63(6):480-485
Postoperative recurrence is one of the primary factors contributing to the poor prognosis of patients with intrahepatic cholangiocarcinoma (ICC). The recurrence patterns of ICC can be classified into intrahepatic,extrahepatic,and intrahepatic-extrahepatic recurrence,while the timing of recurrence can be categorized as very early,early,and late recurrence. Common risk factors for recurrence include positive surgical margins,lymph node metastasis,multifocality,vascular invasion,large tumor size,and concomitant liver cirrhosis. The key to improving the quality of life for ICC patients with postoperative recurrence lies in the accurate preoperative identification of high-risk populations and the implementation of targeted interventions,as well as the formulation of appropriate treatment strategies based on individual patient conditions after recurrence. Interventions for high-risk populations include standardized neoadjuvant therapy,postoperative adjuvant therapy,and high-frequency follow-up. Re-resection remains the most ideal treatment option for recurrence,although the surgical indications are stringent. Non-surgical treatments,including systemic therapy,local therapy,and supportive care,should be tailored to the specific circumstances of each patient.
4.Analysis on the Financing Structural Changes and Influencing Factors of Total Health Expenditure in Inner Mongolia
Jiamei WANG ; Zhiwei QUAN ; Peipei CHAI ; Jing SUN
Chinese Health Economics 2025;44(10):43-46,50
Objective:To analyze the structural changes and influencing factors of Total Health Expenditure(THE)in Inner Mongolia from 2008 to 2023,and provide references for formulating and adjusting relevant health policies in the region.Methods:Structural change degree analysis was used to examine the financing structure of THE,while principal component regression was employed to identify the influencing factors of THE.Results:From 2008 to 2023,THE in Inner Mongolia showed continuous growth,with a significant increase in per capita health expenditure,though there is still room for improvement compared with other regions.Government health expenditure and social health expenditure generally showed positive changes,while individual health expenditure showed negative changes.Per capita disposable income,urbanization rate,and per capita regional GDP were positively correlated with THE,while natural population growth rate and hospital bed utilization rate were negatively correlated with THE.Conclusion:THE in Inner Mongolia continued to grow from 2008 to 2023,but problems such as insufficient government investment and the need to optimize the financing structure existed.Given that economic factors dominate THE growth,it is recommended to achieve reasonable control of THE by improving the efficiency of health resources.
5.Analysis on the Financing Structural Changes and Influencing Factors of Total Health Expenditure in Inner Mongolia
Jiamei WANG ; Zhiwei QUAN ; Peipei CHAI ; Jing SUN
Chinese Health Economics 2025;44(10):43-46,50
Objective:To analyze the structural changes and influencing factors of Total Health Expenditure(THE)in Inner Mongolia from 2008 to 2023,and provide references for formulating and adjusting relevant health policies in the region.Methods:Structural change degree analysis was used to examine the financing structure of THE,while principal component regression was employed to identify the influencing factors of THE.Results:From 2008 to 2023,THE in Inner Mongolia showed continuous growth,with a significant increase in per capita health expenditure,though there is still room for improvement compared with other regions.Government health expenditure and social health expenditure generally showed positive changes,while individual health expenditure showed negative changes.Per capita disposable income,urbanization rate,and per capita regional GDP were positively correlated with THE,while natural population growth rate and hospital bed utilization rate were negatively correlated with THE.Conclusion:THE in Inner Mongolia continued to grow from 2008 to 2023,but problems such as insufficient government investment and the need to optimize the financing structure existed.Given that economic factors dominate THE growth,it is recommended to achieve reasonable control of THE by improving the efficiency of health resources.
6.Clinical and pathological features and prognostic analysis of early-onset intrahepatic cholangiocarcinoma
Delong QIN ; Yue TANG ; Zonglong LI ; Jialu CHEN ; Zhimin GENG ; Chuandong SUN ; Hong WU ; Yinghe QIU ; Tianqiang SONG ; Xianhai MAO ; Yu HE ; Zhangjun CHENG ; Wenlong ZHAI ; Jingdong LI ; Xiao LIANG ; Ruixin LIN ; Di TANG ; Zhaohui TANG ; Zhiwei QUAN
Chinese Journal of Surgery 2025;63(6):500-507
Objective:To explore the clinical and pathological features and survival outcomes of patients with early-onset intrahepatic cholangiocarcinoma (EOICC).Methods:This is a multicenter, retrospective cohort study. Data of 1 160 intrahepatic cholangiocarcinoma patients undergoing radical resection in 14 tertiary Grade A hospitals in China from January 2010 to November 2021 were retrospectively collected. The cohort included 632 males and 528 females, aged( M (IQR)) 61 (14) years (range: 22 to 93 years). ICC aged ≤50 years at the time of diagnosis was defined as EOICC and >50 years as late-onset intrahepatic cholangiocarcinoma (LOICC). Of these, there were 247 cases in the EOICC group and 913 cases in the LOICC. The clinical and pathological characteristics of both groups were analyzed and compared using the independent sample t-test, Mann-Whitney U test or Kaplan-Meier method. Univariate and multivariate Cox regression models for patient outcomes were constructed and forest graphed. Results:Compared with the patients in the LOICC group, patients in the EOICC group had lower carcinoembryonic antigen levels (2.5(4.0) μg/L vs. 3.1(5.2)μg/L, U=124 899, P=0.009) and CA19-9 level (63.4(524.7)U/ml vs. 77.9(611.3)U/ml, U=120 320, P=0.013), higher levels of ALT (29(35)U/L vs. 24(26)U/L, U=101 214, P=0.013), a lower score of the Eastern US Cooperative Oncology Group (0 score patients: 54.7% vs. 44.1%, χ2=12.472, P=0.014), higher TNM stage ( χ2=11.807, P=0.038), and proportion of lymph node dissection (62.3% vs. 54.1%, χ2=5.355, P=0.021). Patients in the two groups in sex, first diagnosis symptoms, intrahepatic bile duct stone history, nail protein, albumin, total bilirubin, transaminase, liver function Child-Pugh grade, T stage, stage, N stage, preoperative laparoscopic exploration proportion, tumor diameter, vascular invasion proportion, differentiation, margin, intraoperative bleeding, postoperative complications, postoperative hospital days were no statistical significance (all P>0.05). Patients in the EOICC group had better outcomes than the LOICC group (median survival time: 29.7 months vs. 25.0 months, 3-year overall survival: 45.1% vs. 37.8%, P=0.027). Conclusion:EOICC patients are better than LOICC patients in carcinoembryonic antigen, CA19-9, ALT, physical strength status and TNM stage, and the long-term prognosis is also better than LOICC patients.
7.Identification and management strategies for postoperative recurrence of intrahepatic cholangiocarcinoma
Delong QIN ; Yue TANG ; Zonglong LI ; Jialu CHEN ; Zhaohui TANG ; Zhiwei QUAN
Chinese Journal of Surgery 2025;63(6):480-485
Postoperative recurrence is one of the primary factors contributing to the poor prognosis of patients with intrahepatic cholangiocarcinoma (ICC). The recurrence patterns of ICC can be classified into intrahepatic,extrahepatic,and intrahepatic-extrahepatic recurrence,while the timing of recurrence can be categorized as very early,early,and late recurrence. Common risk factors for recurrence include positive surgical margins,lymph node metastasis,multifocality,vascular invasion,large tumor size,and concomitant liver cirrhosis. The key to improving the quality of life for ICC patients with postoperative recurrence lies in the accurate preoperative identification of high-risk populations and the implementation of targeted interventions,as well as the formulation of appropriate treatment strategies based on individual patient conditions after recurrence. Interventions for high-risk populations include standardized neoadjuvant therapy,postoperative adjuvant therapy,and high-frequency follow-up. Re-resection remains the most ideal treatment option for recurrence,although the surgical indications are stringent. Non-surgical treatments,including systemic therapy,local therapy,and supportive care,should be tailored to the specific circumstances of each patient.
8.Predict the effect of the number of positive preoperative serum tumor markers on the surgical method and prognosis of intrahepatic cholangiocarcinoma patients based on mediation analysis
Zonglong LI ; Jialu CHEN ; Yue TANG ; Delong QIN ; Chen CHEN ; Yinghe QIU ; Hong WU ; Yu HE ; Xianhai MAO ; Wenlong ZHAI ; Jingdong LI ; Xiao LIANG ; Chuandong SUN ; Kai MA ; Zhimin GENG ; Zhaohui TANG ; Zhiwei QUAN
Chinese Journal of Surgery 2024;62(7):685-696
Objective:To investigate the effect of the number of positive preoperative serological tumor markers on the surgical approach and prognosis of patients with intrahepatic cholangiocarcinoma.Methods:This is a retrospective case-series study. Data from 548 patients with intrahepatic cholangiocarcinoma after radical resection from October 2010 to April 2019 were retrospectively collected in 10 hospitals of China. There were 277 males and 271 females with an age of (57.8±10.2)years(range:23 to 84 years). Four hundred and twenty-six patients(77.7%) had at least one positive preoperative serum tumor marker. The data collection included the results of 4 preoperative serological tumor markers,other preoperative indicators(5 prodromal symptoms, 6 medical history,8 preoperative serological indicators,5 preoperative imaging indicators,and 14 preoperative pathological examination indicators),baseline data (gender and age),surgical methods,and prognostic follow-up data. Four preoperative results of serologic tumor marker and surgical procedure were converted into categorical variables. The number of positive preoperative serum tumor markers was used as the treatment variable,the surgical method was used as the mediating variable,and the survival time was used as the outcome variable. Univariate and multivariate analysis were used to screen for other preoperative indicators which were independent factors that influenced the surgical procedure and the prognosis of patients as covariates to analyze the mediating effect.Results:Of the 548 patients included in the study, 176 patients (32.1%) underwent partial hepatectomy,151 patients(27.5%) underwent hemihepatectomy, and 221 patients(40.3%) underwent partial hepatectomy or hemihepatectomy combined with other treatments. The results of the univariate and multivariate analysis showed that the number of positive serum tumor markers,intrahepatic bile duct dilatation,portal vein invasion,pathological differentiation,pathological type,vascular invasion,T stage,N stage and maximum tumor diameter were independent factors influencing the surgical procedure(all P<0.05). Intrahepatic bile duct dilatation,pathological differentiation and T stage were independent prognostic factors for patients with intrahepatic cholangiocarcinoma(all P<0.05). Intrahepatic bile duct dilatation,differentiation and T stage were included as covariates in the mediation effect model. The results showed that the number of positive serum tumor markers before surgery had a negative predictive effect on the survival time of patients with intrahepatic cholangiocarcinoma ( β=-0.092, P=0.039),and had a positive predictive effect on the surgical method ( β=0.244, P<0.01). The number of positive serum tumor markers had a negative predictive effect on the survival time of patients with intrahepatic cholangiocarcinoma ( β=-0.151, P=0.002). Direct and indirect effects accounted for 71.3% and 28.7% of total effects,respectively. Conclusions:The higher the positive number of preoperative tumor markers,the worse the prognosis of patients with intrahepatic cholangiocarcinoma. The number of positive cells not only directly affects the prognosis of patients,but also indirectly affects the prognosis of patients by affecting the surgical method.
9.The research on early-onset intrahepatic cholangiocarcinoma should be taken seriously
Delong QIN ; Jialu CHEN ; Yue TANG ; Zonglong LI ; Zhaohui TANG ; Zhiwei QUAN
Journal of Clinical Hepatology 2024;40(12):2345-2350
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant biliary tumor, and early-onset ICC (EOICC) refers to ICC with an age of ≤50 years at the time of confirmed diagnosis and often has a higher clinical stage and more significant biological invasiveness. At present, the incidence rate of EOICC is increasing rapidly, but the research on EOICC is still in its early stage. Current evidence has shown that EOICC has significantly different epidemiological, clinical, and molecular characteristics from late-onset ICC. Therefore, the research on the high-risk factors and pathogenesis of EOICC is of great importance for the early identification, diagnosis, and targeted treatment of EOICC. Due to the younger age and better physical condition of EOICC patients, they can tolerate medical interventions with higher risks, and active individualized diagnosis and treatment regimens can be adopted, allowing patients to obtain similar survival and prognosis as those with late-onset ICC. However, due to the significant differences in molecular characteristics between EOICC and ICC, existing targeted drugs may not be suitable for EOICC patients, posing a huge challenge for the systematic treatment of patients with advanced EOICC. The clinical and basic research on EOICC is still lagging behind, and the population characteristics and pathogenic factors of EOICC should be further clarified, in order to promote the establishment of prevention, diagnosis, and treatment standards for the EOICC population.
10.Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients (version 2024)
Yao LU ; Yang LI ; Leiying ZHANG ; Hao TANG ; Huidan JING ; Yaoli WANG ; Xiangzhi JIA ; Li BA ; Maohong BIAN ; Dan CAI ; Hui CAI ; Xiaohong CAI ; Zhanshan ZHA ; Bingyu CHEN ; Daqing CHEN ; Feng CHEN ; Guoan CHEN ; Haiming CHEN ; Jing CHEN ; Min CHEN ; Qing CHEN ; Shu CHEN ; Xi CHEN ; Jinfeng CHENG ; Xiaoling CHU ; Hongwang CUI ; Xin CUI ; Zhen DA ; Ying DAI ; Surong DENG ; Weiqun DONG ; Weimin FAN ; Ke FENG ; Danhui FU ; Yongshui FU ; Qi FU ; Xuemei FU ; Jia GAN ; Xinyu GAN ; Wei GAO ; Huaizheng GONG ; Rong GUI ; Geng GUO ; Ning HAN ; Yiwen HAO ; Wubing HE ; Qiang HONG ; Ruiqin HOU ; Wei HOU ; Jie HU ; Peiyang HU ; Xi HU ; Xiaoyu HU ; Guangbin HUANG ; Jie HUANG ; Xiangyan HUANG ; Yuanshuai HUANG ; Shouyong HUN ; Xuebing JIANG ; Ping JIN ; Dong LAI ; Aiping LE ; Hongmei LI ; Bijuan LI ; Cuiying LI ; Daihong LI ; Haihong LI ; He LI ; Hui LI ; Jianping LI ; Ning LI ; Xiying LI ; Xiangmin LI ; Xiaofei LI ; Xiaojuan LI ; Zhiqiang LI ; Zhongjun LI ; Zunyan LI ; Huaqin LIANG ; Xiaohua LIANG ; Dongfa LIAO ; Qun LIAO ; Yan LIAO ; Jiajin LIN ; Chunxia LIU ; Fenghua LIU ; Peixian LIU ; Tiemei LIU ; Xiaoxin LIU ; Zhiwei LIU ; Zhongdi LIU ; Hua LU ; Jianfeng LUAN ; Jianjun LUO ; Qun LUO ; Dingfeng LYU ; Qi LYU ; Xianping LYU ; Aijun MA ; Liqiang MA ; Shuxuan MA ; Xainjun MA ; Xiaogang MA ; Xiaoli MA ; Guoqing MAO ; Shijie MU ; Shaolin NIE ; Shujuan OUYANG ; Xilin OUYANG ; Chunqiu PAN ; Jian PAN ; Xiaohua PAN ; Lei PENG ; Tao PENG ; Baohua QIAN ; Shu QIAO ; Li QIN ; Ying REN ; Zhaoqi REN ; Ruiming RONG ; Changshan SU ; Mingwei SUN ; Wenwu SUN ; Zhenwei SUN ; Haiping TANG ; Xiaofeng TANG ; Changjiu TANG ; Cuihua TAO ; Zhibin TIAN ; Juan WANG ; Baoyan WANG ; Chunyan WANG ; Gefei WANG ; Haiyan WANG ; Hongjie WANG ; Peng WANG ; Pengli WANG ; Qiushi WANG ; Xiaoning WANG ; Xinhua WANG ; Xuefeng WANG ; Yong WANG ; Yongjun WANG ; Yuanjie WANG ; Zhihua WANG ; Shaojun WEI ; Yaming WEI ; Jianbo WEN ; Jun WEN ; Jiang WU ; Jufeng WU ; Aijun XIA ; Fei XIA ; Rong XIA ; Jue XIE ; Yanchao XING ; Yan XIONG ; Feng XU ; Yongzhu XU ; Yongan XU ; Yonghe YAN ; Beizhan YAN ; Jiang YANG ; Jiangcun YANG ; Jun YANG ; Xinwen YANG ; Yongyi YANG ; Chunyan YAO ; Mingliang YE ; Changlin YIN ; Ming YIN ; Wen YIN ; Lianling YU ; Shuhong YU ; Zebo YU ; Yigang YU ; Anyong YU ; Hong YUAN ; Yi YUAN ; Chan ZHANG ; Jinjun ZHANG ; Jun ZHANG ; Kai ZHANG ; Leibing ZHANG ; Quan ZHANG ; Rongjiang ZHANG ; Sanming ZHANG ; Shengji ZHANG ; Shuo ZHANG ; Wei ZHANG ; Weidong ZHANG ; Xi ZHANG ; Xingwen ZHANG ; Guixi ZHANG ; Xiaojun ZHANG ; Guoqing ZHAO ; Jianpeng ZHAO ; Shuming ZHAO ; Beibei ZHENG ; Shangen ZHENG ; Huayou ZHOU ; Jicheng ZHOU ; Lihong ZHOU ; Mou ZHOU ; Xiaoyu ZHOU ; Xuelian ZHOU ; Yuan ZHOU ; Zheng ZHOU ; Zuhuang ZHOU ; Haiyan ZHU ; Peiyuan ZHU ; Changju ZHU ; Lili ZHU ; Zhengguo WANG ; Jianxin JIANG ; Deqing WANG ; Jiongcai LAN ; Quanli WANG ; Yang YU ; Lianyang ZHANG ; Aiqing WEN
Chinese Journal of Trauma 2024;40(10):865-881
Patients with severe trauma require an extremely timely treatment and transfusion plays an irreplaceable role in the emergency treatment of such patients. An increasing number of evidence-based medicinal evidences and clinical practices suggest that patients with severe traumatic bleeding benefit from early transfusion of low-titer group O whole blood or hemostatic resuscitation with red blood cells, plasma and platelet of a balanced ratio. However, the current domestic mode of blood supply cannot fully meet the requirements of timely and effective blood transfusion for emergency treatment of patients with severe trauma in clinical practice. In order to solve the key problems in blood supply and blood transfusion strategies for emergency treatment of severe trauma, Branch of Clinical Transfusion Medicine of Chinese Medical Association, Group for Trauma Emergency Care and Multiple Injuries of Trauma Branch of Chinese Medical Association, Young Scholar Group of Disaster Medicine Branch of Chinese Medical Association organized domestic experts of blood transfusion medicine and trauma treatment to jointly formulate Chinese expert consensus on blood support mode and blood transfusion strategies for emergency treatment of severe trauma patients ( version 2024). Based on the evidence-based medical evidence and Delphi method of expert consultation and voting, 10 recommendations were put forward from two aspects of blood support mode and transfusion strategies, aiming to provide a reference for transfusion resuscitation in the emergency treatment of severe trauma and further improve the success rate of treatment of patients with severe trauma.

Result Analysis
Print
Save
E-mail